Jay joined Abingworth’s Menlo Park office in August 2021, bringing more than 15 years of experience in investment, consulting and academic research in the life sciences industry.
Previously, Jay was a Director at AbbVie Ventures, the corporate venture capital arm of AbbVie, focusing on early-stage biotech investments. He played an instrumental role in their investments in Accent Therapeutics and Caribou Biosciences (NASDAQ:CRBU) and supported portfolio companies including Disarm Therapeutics (acquired by Lilly) and Jnana Therapeutics. Jay was also responsible for sourcing multiple seed-stage opportunities and formulating theses in key investment areas. Before AbbVie, Jay worked as a management consultant at ZS Associates and as the leader of an NIH-funded drug discovery research lab in Chicago.
Jay holds a PhD in organic chemistry from the University of Chicago and an MBA with honours from the University of Chicago Booth School of Business.